Establishment Labs (NASDAQ:ESTA) Announces Earnings Results, Beats Estimates By $0.08 EPS
Establishment Labs (NASDAQ:ESTA) released its earnings results on Tuesday. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.08, Fidelity Earnings reports. The firm had revenue of $21.68 million during the quarter, compared to analyst estimates of $20.10 million. Establishment Labs had a negative return on equity of 68.22% and a negative net margin of 37.74%. Establishment Labs updated its FY 2019 guidance to EPS.
NASDAQ:ESTA traded down $0.54 during midday trading on Wednesday, reaching $22.00. The company had a trading volume of 5,657 shares, compared to its average volume of 61,615. The firm has a market cap of $505.56 million and a price-to-earnings ratio of -19.64. The business’s fifty day simple moving average is $22.89. Establishment Labs has a 12-month low of $20.05 and a 12-month high of $30.70. The company has a debt-to-equity ratio of 0.38, a current ratio of 5.54 and a quick ratio of 4.10.
A number of research analysts recently issued reports on the company. Wells Fargo & Co set a $29.00 target price on Establishment Labs and gave the company a “buy” rating in a report on Friday, July 12th. BTIG Research reiterated a “buy” rating and issued a $40.00 target price on shares of Establishment Labs in a report on Thursday, May 16th. ValuEngine upgraded Establishment Labs from a “hold” rating to a “buy” rating in a report on Monday, July 29th. Finally, Stephens assumed coverage on Establishment Labs in a report on Thursday, June 6th. They issued an “overweight” rating and a $37.00 target price for the company. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $35.33.
About Establishment Labs
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.
Recommended Story: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.